Antibodies remained high 6 months after the second Moderna dose
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
We describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult participants in an ongoing phase 1 trial, stratified according to age, at 180 days after the second dose of 100 μg (day 209). Antibody activity remained high in all age groups at day 209. These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
We previously reported that plasma from persons infected with the original variant showed substantially lower neutralization of the 501Y.V2 variant than of the original variant (Figures 1A and S4A). In the current study, we performed the reverse experiment by assessing the cross-reactivity of the plasma neutralizing responses in the Groote Schuur Hospital cohort of patients with 501Y.V2 infection against the original variant and against 501Y.V3 (P.1), the variant first described in Brazil. We first tested 57 plasma samples from patients at Groote Schuur Hospital against both 501Y.V2 and the original variant and found that 53 of 57 samples maintained neutralization activity against the original variant, with a geometric mean titer of 203 (95% confidence interval, 141 to 292), approximately one third of the titer against the 501Y.V2 variant (Figures 1B and S5A).
Transmission of COVID-19 in school settings and interventions to reduce transmission: A rapid review
Evidence from 39 observational studies (11 preprints, 2 reports) predominantly suggests that transmission within schools can be limited when infection prevention and control (IPC) measures are in place. However, transmission may occur, especially in area of high transmission. These results are mainly based on descriptive observational studies (which have no comparator group) and it was not always possible to determine transmission routes.
Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries
We sourced data from 21 countries (16 high-income and five upper-middle-income countries), including whole-country data in ten countries and data for various areas in 11 countries). Rate ratios (RRs) and 95% CIs based on the observed versus expected numbers of suicides showed no evidence of a significant increase in risk of suicide since the pandemic began in any country or area. There was statistical evidence of a decrease in suicide compared with the expected number in 12 countries or areas: New South Wales, Australia (RR 0·81 [95% CI 0·72–0·91]); Alberta, Canada (0·80 [0·68–0·93]); British Columbia, Canada (0·76 [0·66–0·87]); Chile (0·85 [0·78–0·94]); Leipzig, Germany (0·49 [0·32–0·74]); Japan (0·94 [0·91–0·96]); New Zealand (0·79 [0·68–0·91]); South Korea (0·94 [0·92–0·97]); California, USA (0·90 [0·85–0·95]); Illinois (Cook County), USA (0·79 [0·67–0·93]); Texas (four counties), USA (0·82 [0·68–0·98]); and Ecuador (0·74 [0·67–0·82]). This is the first study to examine suicides occurring in the context of the COVID-19 pandemic in multiple countries. In high-income and upper-middle-income countries, suicide numbers have remained largely unchanged or declined in the early months of the pandemic compared with the expected levels based on the pre-pandemic period.